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Abstract 29 
Objectives: To investigate the population pharmacokinetics (PK) of amoxicillin in ICU burn 30 
patients and the optimal dosage regimens. 31 
 32 
Methods: Prospective study involving 21 consecutive burn patients receiving amoxicillin. PK 33 
data were analysed using non-linear mixed effects modelling. Monte-Carlo simulations 34 
assessed the influence of various amoxicillin dosage regimens with identified covariates on 35 
the probability to achieve a target (PTA) value of time during which free amoxicillin 36 
concentrations in plasma exceeded the minimal inhibitory concentration (fT>MIC).  37 
 38 
Results: A two-compartment model best described the data. Creatinine clearance (CLCR) and 39 
body weight (BW) influenced amoxicillin CL and central volume of distribution (V1), 40 
respectively. The median CLCR (Cockcroft-Gault formula) was high (128 mL/min) with 25% 41 
of patients having CLCR > 150 mL/min. The CL, V1 and t½ values at steady-state for a patient 42 
with a CLCR of 110 mL/min and BW of 70 kg were 13.6 L/h, 9.7 L and 0.8 h, respectively. 43 
Simulations showed that a target fT>MIC ≥ 50% was achieved (PTA > 90%) with standard 44 
amoxicillin dosage regimens (1-2 g q6-8 h) when the MIC was low (< 1 mg/L). However, 45 
increased dosages of up to 2 g/4 h were necessary in patients with augmented CLR or higher 46 
MIC. Prolonging amoxicillin infusion from 30 min to 2 h had a favourable effect on target 47 
attainment. 48 
 49 
Conclusion: This population analysis shows an increased amoxicillin CL and substantial CL 50 
PK variability in burn patients compared to literature data with non-burn patients. Situations 51 
of augmented CLCR and/or high bacterial MIC target values may require dosage increases and 52 
longer infusion durations. 53 
 54 
Keywords: Amoxicillin, pharmacokinetics, burn patients. 55 
 56 
 57 
 58 
 59 
 60 
 61 
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Introduction 62 
Treating sepsis promptly and adequately in burn patients is crucial as it is still the 63 
predominant cause of morbidity and mortality despite major advances in hemodynamic and 64 
respiratory support (1-5). In this context, optimizing antibiotic dosage regimens to improve 65 
clinical outcomes and to avoid antibiotic resistance is desirable (6). However, this task is 66 
highly complex as it not only requires a well-trained multidisciplinary team but also extended 67 
knowledge of pharmacokinetic (PK) alterations due to burn trauma (7-9). Therapeutic drug 68 
monitoring (TDM) appears to be a useful intervention to ensure attainment of 69 
PK/pharmacodynamic (PD) surrogate indicators of antibiotic efficacy to counteract the well 70 
documented intervariability PK observed in this population (10-15). Moreover, TDM might 71 
also potentially improve burn patient outcomes (10, 12, 16, 17). Currently, the Bayesian 72 
forecasting approach for estimation of individual PK parameters represents the gold-standard 73 
approach for TDM (18, 19). 74 
Amoxicillin is frequently used as a first-line antibiotic treatment in burn patients 75 
during the first weeks of hospitalization (14). It is partially metabolized by the hepatic system 76 
and lowly protein-bound (18%) (20). As this antibiotic is excreted in the urine (60% 77 
unchanged), its elimination is slowed in case of renal impairment. TDM of amoxicillin is 78 
available but rarely used in our institution, including in the Burn Centre, as beta-lactam 79 
antibiotics are often thought to have few dose-dependent side effects and a wide therapeutic 80 
margin (21). 81 
Because significant PK changes of antibacterial agents have been reported in burn 82 
patients, such patients are considered as a special population in clinical PK studies (9, 22). For 83 
beta-lactams, most reports indicate increased values of drug CL and volume of distribution in 84 
burn patients compared to healthy subjects (9). Because of these alterations, dose 85 
requirements of antibiotics may be increased in this population. However, few reports have 86 
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4 
addressed the PK profile in burn patients and are based on a small number of individuals. The 87 
use of a population approach to characterize amoxicillin PK and its variability and identify 88 
sources of variability has rarely been performed in burn patients. 89 
In this context, our study aimed at determining the PK profile of intravenous 90 
amoxicillin given to adult patients with severe burns hospitalized in the Burn Centre of our 91 
hospital. The population model served to evaluate the PK/PD target attainment using standard 92 
and alternative dosage regimens of amoxicillin. 93 
 94 
Materials and Methods 95 
Ethics 96 
This study was approved by the Institutional Review Board of the Centre Hospitalier 97 
Universitaire Vaudois and the Ethics Committee of the State of Vaud, Switzerland (protocole 98 
195/13). Written informed consent was obtained from each patient. 99 
 100 
Study design and setting 101 
We prospectively and consecutively enrolled all burn patients admitted to the Burn Centre of 102 
our hospital who received a course of intravenous amoxicillin administered either alone or in 103 
combination with clavulanic acid from October 2013 to October 2016. The Burn Centre is a 104 
five-bed Swiss tertiary ICU nested in a 35-bed medical surgical ICU. This study was 105 
registered on the https://clinicaltrials.gov/ platform (Trial Registration: NCT01965340). 106 
 107 
Data collection 108 
Age, sex, weight, CLCR (Cockcroft-Gault formula) and burn characteristics (including total 109 
burnt body surface area and Ryan score (23)) were collected from medical records for each 110 
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burn patient hospitalized during the study period. Data regarding amoxicillin administration 111 
(including date and time of administration, dose administered and duration of infusion) were 112 
prospectively collected from our computerized information system (Metavision; IMDsoft, Tel 113 
Aviv, Israel). For each episode of infection, the microorganism was systematically identified, 114 
if possible. The susceptibility of amoxicillin was determined using E-Test for each patient in 115 
whom the microorganism was identified (24, 25). 116 
 117 
Antimicrobial treatment 118 
Amoxicillin Clamoxyl (GlaxoSmithKline AG, Münchenbuchsee) or Co-Amoxi-Mepha 119 
(Mepha Schweiz AG, Basel) was dosed in accordance with the manufacturer’s 120 
recommendations (1-2 g every 6–8 h in patients with normal renal function) and infused over 121 
2 h (amoxicillin) or 1 h (amoxicillin/clavulanic acid) starting from the second dose (over 30 122 
min for the first dose) according to our local guidelines. Indeed, amoxicillin/clavulanic acid 123 
solutions (diluted with 0.9% NaCl) have limited stability and, therefore, the maximal infusion 124 
time was set to 1 h. In contrast, as amoxicillin alone is more stable (stability of  3 h or 6 h 125 
when diluted in Ringer’s lactate solution or 0.9% NaCl, respectively (20)), an extended 126 
perfusion (2 h) could be used. For patients with renal insufficiency, the dosage was adjusted 127 
according to the renal function estimated by the Cockcroft-Gault equation (eGFR < 30 128 
ml/min: 500 mg–2 g q8-12 h; eGFR < 15 ml/min: 750 mg–2 g q24 h).   129 
 130 
Blood concentration measurements 131 
Blood samplings for the amoxicillin assay were performed at various time points. Trough 132 
levels were sampled on days 2, 4, 6 and 8. Additional samples were obtained every 2 days in 133 
a few patients who received a course longer than 8 days. Random levels were sampled on day 134 
6 and day 8. A rich amoxicillin kinetic profile was obtained on one occasion for most patients 135 
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(18 out of 21, including one patient with two rich profiles) at the following sampling times: 0, 136 
1, 2, 3, 4 and 5 h after the end of the infusion. The exact times were adjusted according to the 137 
infusion duration.  138 
 139 
Determination of amoxicillin concentrations 140 
Amoxicillin plasma levels were determined using a multiplex assay by ultra-performance 141 
liquid chromatography coupled to tandem mass spectrometry (UPLC-MS/MS) requiring 100 142 
L of plasma for the simultaneous quantification within 9 min of 12 most recommended and 143 
frequently used antibacterial drugs (see Supplemental Material)(26). As no assay method 144 
was available for clavulanic acid, its concentration was not determined in this study. Blood 145 
samples were directly sent to the laboratory after sampling and were stored at -80°C until the 146 
analysis. Analyses were performed within 6 hours during the week. Samples collected over 147 
the weekend were analyzed the following Monday afternoon.  148 
 149 
Population PK model building 150 
NONMEM version 7.1.0 (ICON Development Solutions, Ellicott City, MD, USA) was used 151 
to analyse amoxicillin plasma concentrations versus time data using a non-linear mixed-152 
effects modelling approach. The first-order conditional estimation with the interaction 153 
algorithm was selected for all runs. We assumed log-normal distributions of PK parameters, 154 
i.e. an exponential model for interindividual variability. First, the best structural model and 155 
residual error models were identified. One-, two- and three-compartment open linear models 156 
were evaluated. For the residual error, proportional, additive and combined (additive plus 157 
proportional) error models were tested.  158 
Next, covariate model building was performed using the Stepwise Covariate Model 159 
building tool of Perl Speaks to NONMEM (27). This tool permits forward selection and 160 
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7 
backward deletion of covariates in a model in a comprehensive manner. The following 161 
covariates were investigated: sex, total body surface area, serum albumin, serum creatinine, 162 
CLCR (estimated by the Cockcroft-Gault equation), actual body weight (BW), BW on 163 
admission (BWADM), BW gain (defined as BW – BWADM when BW > BWADM and zero 164 
otherwise), and BW loss (defined as BWADM – BW when BWADM > BW and zero otherwise). 165 
Linear relationships were tested for categorical covariates, while linear and power functions 166 
were tested for continuous covariates. The change in the objective function value (OFV) was 167 
used to assess the influence of covariates, assuming a chi-squared distribution of the OFV, 168 
with one degree of freedom for each addition of a linear power relation. Statistical 169 
significance was set at a p-value of 0.05 for forward selection and 0.01 for backward deletion. 170 
 171 
Final model evaluation 172 
Internal model validation was based on standard criteria (28): the OFV as described 173 
above, parameter estimates along with their standard errors, plots of observed amoxicillin 174 
concentration versus population and individual predictions, and plots of conditional weighted 175 
residuals (29). A bootstrap analysis (n = 1000 samples with replacement from the original 176 
dataset) was carried out with the PsN tool kit to check the uncertainty of parameter estimates 177 
and derive the 95% CI. A visual predictive inspection was also performed by comparing the 178 
observed amoxicillin concentration with model-based simulations (n = 1000 samples for each 179 
patient)(30).  180 
 181 
Dosing simulations 182 
PK/PD simulations were performed based on the final model to investigate the influence of 183 
amoxicillin dose, dose interval, infusion duration and covariates (renal function) on the 184 
probability to achieve a target exposure for amoxicillin. All simulations and calculations of 185 
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probabilities of target attainment were done with the Pmetrics R package (31). Mean and 186 
variance of parameters of the final model estimated with NONMEM were imported into 187 
Pmetrics. We tested three amoxicillin doses (0.5, 1 and 2 g), five dosing intervals (4, 6, 8, 12 188 
and 24 h), and two infusion times (30 min and 2 h). As CLCR was found to influence 189 
amoxicillin CL, we considered six levels of renal function: 15, 30, 60, 100, 150 and 200 190 
mL/min. For each condition, 500 virtual patients were created based on parameter estimates 191 
and covariates retained in the final NONMEM model. Amoxicillin CL values were randomly 192 
sampled based on the final estimates of mean and variance. The Q and V2 values were fixed 193 
to their final NONMEM estimates for all subjects. Since BW influenced V1, this value 194 
changed as a function of BW. BW was sampled from a log-normal distribution in the form of 195 
89 × exp(ηBW), with ηBW ~ N(0, 0.184
2
). These values were representative of the average BW 196 
(89 kg) during antibiotic therapy and variability in a group of 39 burn patients from our Burn 197 
Centre who received a beta-lactam antibacterial agent (data not shown), including the 21 burn 198 
patients involved in this study. 199 
Steady-state (i.e. after 10 days of therapy) amoxicillin concentration profiles were 200 
simulated for each condition. Then, we derived probabilities of target attainment (PTA) using 201 
the dedicated function in Pmetrics. The PK/PD target was defined as a percentage of time 202 
during which the free amoxicillin concentration in plasma exceeds the MIC (fT>MIC). Two 203 
targets were considered:  a target of fT>MIC ≥ 50% usually recognized as efficient for -204 
lactams (such as penicillins and carbapenems) (32-35), and a more conservative target of 205 
fT>MIC = 100%, which seems to be associated with better outcomes in critically ill patients 206 
(11, 36). We considered MIC values of 0.25, 0.5, 1, 2, 4, 8 and 16 mg/L as 8 mg/L is the 207 
highest amoxicillin MIC breakpoint value for several Gram-negative organisms, including 208 
Escherichia coli, according to the European Committee on Antimicrobial Susceptibility 209 
Testing (37). We assumed a free fraction of 82% for amoxicillin (38). In addition, we 210 
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considered 90% as an optimal PTA to be achieved, as suggested by the European Medicines 211 
Agency (39). 212 
The influence of BW on PTA was also examined using the same approach. We 213 
considered situations of low weight (50 kg), standard weight (70 kg), overweight (100 kg) and 214 
obesity (150 kg) as well as three levels of renal function (30, 100 and 200 mL/min) for each 215 
weight. A dosage regimen of 1 g q8h (infused over 30 min) was simulated in 500 virtual 216 
patients in all 12 conditions, and steady-state concentrations were analysed. 217 
 218 
Results 219 
Patient characteristics and microbiological data 220 
A total of 185 amoxicillin concentrations were obtained from 21 burn patients aged from 16 221 
to 93 years. The patients’ body weight on admission ranged from 60 to 132 kg. Table 1 222 
presents the characteristics of the population. There was a large majority of male patients. The 223 
median CLCR was high (128 mL/min), with 25% of patients having CLCR > 150 mL/min. The 224 
median BW on admission was 72.4 kg, with a coefficient of variation of 22%. Limited intra-225 
individual variability was observed in BW during the course of amoxicillin ( clavulanic acid) 226 
therapy, with a median change in BW of -2.3% (minimum, -11.4%; maximum, +10.6%). Of 227 
note, some patients had several episodes of infection that were treated by amoxicillin (± 228 
clavulanic acid). Microorganism identification with susceptibility was obtained at least once 229 
for 16 out of 21 patients. Two different bacteria were identified in the same sample for three 230 
patients, and one patient presented the same bacteria (Staphylococcus aureus) in two distinct 231 
tissue samples. As a result, a total of 20 susceptibilities were determined. Table 2 summarizes 232 
the microbiological data. 233 
 234 
 235 
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 236 
 237 
Population PK model 238 
The final model was a two-compartment model with the following parameters: amoxicillin 239 
CL, central (V1) and peripheral (V2) volumes of distribution, and intercompartmental 240 
clearance (Q).  241 
Residual variability was best described by a combined additive and proportional residual error 242 
model. The stepwise covariate modelling approach identified CLCR and BW as covariates 243 
influencing amoxicillin CL and V1, respectively. CLCR was found to influence amoxicillin CL 244 
in a linear manner, and V1 was allometrically scaled to the actual BW. Amoxicillin CL was 245 
the only random PK parameter, while the others had a fixed, estimated value. Models 246 
incorporating between subject variability on V1, V2 and Q were tested. As they either did not 247 
improve the model fit or poorly estimated the corresponding random effects (high standard 248 
errors), interindividual variabilities were not estimated for those parameters in the final 249 
model. Interoccasion variability could not be tested owing to the sampling design, which 250 
prevented from discriminating between interoccasion and intrapatient variabilities. Table 3 251 
displays the final estimates of population PK parameters, bootstrap estimates as well as 252 
parameter–covariate relationships. All parameters were estimated with acceptable precision. 253 
Figure 1 shows the plots of conditional weighted residuals versus population 254 
predictions and time. Most residuals were within the expected range (-2; +2), and no major 255 
trend was observed versus prediction or time. The prediction-corrected visual predictive 256 
check obtained with the final model is shown in Figure 2. As a good agreement was observed 257 
between measured amoxicillin concentrations and model-based predictions (Figure 3), the 258 
model was deemed to be appropriate for further dosing simulations. 259 
 260 
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 261 
 262 
Dosage regimen simulations 263 
The Monte-Carlo simulation results are summarized in Figure 4. As expected, when all other 264 
factors were kept constant, the values of fT>MIC and PTA decreased with increasing renal 265 
function and MIC values. 266 
Considering fT>MIC ≥ 50% as the target, in patients with normal renal function (CLCR 267 
= 100 mL/min), the standard dosage regimens with a 30-min infusion of 1-2 g q6-8 h were 268 
adequate for MIC values ≤ 2 mg/L but failed to achieve 90% PTA for higher MIC values. For 269 
a MIC of 8 mg/L, such a PTA was only achieved with the most intensive dosage of 2 g/4 h 270 
and extended infusion (2 h) of 1 g/4 h or 2 g/6 h. The results were quite similar in patients 271 
with moderately impaired renal function (CLCR = 60 ml/min), with 2 g/8 h administered as a 272 
2-h infusion also being effective for high MIC values. In order to achieve the target of 273 
fT>MIC = 100%, regimens of 1 to 2 g administered every 4 h were necessary for MIC values 274 
≤ 2 mg/L. However, for a high MIC of 8 mg/L, even an extended infusion of 2 g q4 h failed to 275 
achieve 90% PTA in simulated patients with CLCR = 100 ml/min.  276 
In patients with augmented renal clearance (200 mL/min), the minimum dose to 277 
achieve the desired 90% PTA for the low target (fT>MIC ≥ 50%) with MIC values  1 mg/L 278 
was 1g q6 h (Figure 4). For higher MIC values, prolonging the infusion duration was 279 
effective for obtaining a higher PTA, and a 2-h infusion of 2 g every 4 h was the only regimen 280 
associated with PTA > 90% for a MIC of 8 mg/L. None of the tested regimens was associated 281 
with acceptable PTA for the high target when the MIC was > 2 mg/L.  282 
In patients with renal impairment (15 and 30 mL/min), reduced dosages (0.5 or 1 g 283 
q12h) appeared to be adequate for low MIC values but were not sufficient for MIC values as 284 
high as 8 mg/L. In this case, a standard dosage (1-2 g q6-8 h) appeared necessary to achieve 285 
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fT>MIC ≥ 50%, while regimens of 1 g q4 h and 2 g q4 h were necessary to achieve fT>MIC = 286 
100% with acceptable PTA in patients with CLCR of 15 and 30 ml/min, respectively. 287 
BW had a limited influence on fT>MIC and PTA, as shown in Table 4. The index 288 
fT>MIC slightly increased with an increasing BW as a result of a decrease in the distribution 289 
(K12 = Q/V) and elimination rate constants (Ke = CL/V). However, even a three-fold increase 290 
in BW only had a modest effect on PTA.  291 
 292 
Discussion 293 
Although amoxicillin is frequently prescribed in patients with severe burns, to the best 294 
of our knowledge, this is the first population analysis carried out in this population. Literature 295 
regarding the PK of amoxicillin in non-burn patients exists but is scarce (36, 40-42). Our 296 
study provides several insights regarding the PK and dosage requirements of amoxicillin in 297 
this population with known distinct PK characteristics. The PK of burn patients is indeed 298 
altered due to different phenomena, such as capillary leak syndrome, mechanical ventilation, 299 
hypoalbuminemia, extracorporeal circuits and post-chirurgical drains; in addition, significant 300 
burn injuries themselves might increase the volume of distribution of hydrophilic drugs (43-301 
48). 302 
 Our results are in good agreement with a recent population PK study of 303 
amoxicillin/clavulanic acid in 13 ICU adult patients (36), with comparable patient 304 
characteristics (except for burns). While the typical values of volumes of distribution were 305 
similar (V1 and V2), patients in the present study showed a 21% increased CL and a 22% 306 
increased Q in patients with normal renal function (CLCR of 110 mL/min) compared to the 307 
ICU patients without burns. Our results confirm the increase in CL reported for other beta-308 
lactam agents in burn patients, irrespective of renal function (10, 15). We did not observe any 309 
difference in amoxicillin volume of distribution in comparison to the non-burn population 310 
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13 
(36, 49, 50). The covariate analysis confirmed that CLCR influences amoxicillin CL, as 311 
previously described (36). We also found that BW influences V1, suggesting an approximate 312 
doubling of this value from 70 kg to 132 kg. This will reflect in a slightly longer elimination 313 
half-life in overweight patients. Renal function explained 35% of the initial estimated 314 
interpatient variability on amoxicillin clearance, which remains still largely unexplained. This 315 
large variability could be the due to several factors related to patients’ characteristics, burn 316 
consequences and medical support that can affect drug concentrations.  317 
In critically ill patients (including burn patients), evidence suggests that patients may 318 
have a higher CLCR even in the presence of normal plasma creatinine concentrations (51, 52). 319 
An augmented CLR (i.e. CLCR > 130 mL/min) has been reported to occur in 15–65% of ICU 320 
patients including burn patients and therefore increasing the risk of subtherapeutic 321 
concentrations in this population (15, 53). Based on our simulations, our data showed that in 322 
patients with a CLCR = 150 to 200 mL/min, the standard dosage achieved the desired 90% 323 
PTA only for cock values < 1 mg/L. In those patients, dosages as high as 2 g or 4 g appear 324 
necessary to achieve fT>MIC ≥ 50% for the highest MIC breakpoint (8 mg/L). Prolonging the 325 
amoxicillin infusion from 30 min to 2 h was also a way to increase the target attainment.  As 326 
more aggressive pathogens are commonly found in the ICU, the prescription of antibiotics has 327 
to be adapted and carefully monitored among burn patients (10). The standard amoxicillin 328 
dose of 1-2 g q6-8 h results in adequate exposure (fT>MIC ≥ 50%) for both low and normal 329 
CLCR in the case of MIC values of  2 mg/L. However, a higher dosage regimen should be 330 
used to treat burn patients infected by microorganisms with higher MIC. This may be 331 
especially relevant for the treatment of infection caused by Enterobacteriaceae with 332 
amoxicillin/clavulanic acid, as those bacteria often display high MIC values ranging from 2 to 333 
8 mg/L. 334 
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Achieving fT>MIC = 100% with acceptable PTA for MIC values as high as 8 mg/L 335 
was only possible in patients with severe renal impairment. In burn patients with normal or 336 
augmented renal clearance, our results showed that achieving this target was hardly possible 337 
even with the highest dosage of amoxicillin (12 g/day) and repeated extended infusions.  Yet, 338 
the clinical benefits of targeting fT>MIC = 100% remains unclear.  In the DALI study 339 
performed in critically ill patients who received intravenous beta-lactams, there was no 340 
difference in the predictive value of positive clinical outcomes following either fT>MIC = 341 
100% or fT>MIC ≥ 50% (11). In addition, targeting fT>MIC = 100% in all burn patients 342 
would require larger doses and concentrations of amoxicillin that could increase its toxicity 343 
without a thorough monitoring by TDM. Indeed, adverse reactions such as crystalluria have 344 
been reported with the use of high doses of amoxicillin (54, 55). Unlike renal function, inter-345 
individual changes in BW did not appear to have a clinically relevant influence on amoxicillin 346 
PD in adult burn patients.  347 
Our simulation results are somewhat different from those described by Carlier et al 348 
(36). They reported that a fT>MIC of 50% or even 100% would be achieved in most ICU 349 
patients treated with standard doses of amoxicillin (3–4 g in three or four administrations per 350 
day), except for the conditions of augmented CLR combined with the highest bacterial MIC. 351 
Our less optimistic results in burn patients are likely due to the increased Q and CL values 352 
discussed above. In addition, the proportion of simulated patients associated with successful 353 
treatment was not clearly stated in the work by Carlier et al.  354 
As shown for other time-dependent beta-lactam agents (56, 57), increasing the 355 
infusion time of amoxicillin may be a simple way to optimize fT>MIC and drug response. 356 
Amoxicillin combined with clavulanic acid is less stable than amoxicillin alone due to the 357 
degradation of clavulanic acid catalysed by both acids and bases when dissolved in aqueous 358 
solution (58). However, a recent study has demonstrated that amoxicillin alone is stable 359 
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enough to be administered as a continuous infusion and that the combination of amoxicillin 360 
and clavulanic acid is stable for 2 h (58). As our data showed that prolonging the infusion 361 
duration was effective for obtaining a higher PTA in burn patients treated with amoxicillin, 362 
we therefore recommend that an extended infusion of 2 h could be used in cases of infections 363 
caused by microorganisms with high MIC values. 364 
Optimizing antibiotic exposure in the burn population is of high importance as 60% of 365 
these patients fail to reach the PK/PD target of fT>MIC = 100% while receiving betalactams 366 
(12). In order to counteract the PK variability observed in this frail population, it has now 367 
been demonstrated that TDM is a valuable intervention that should be widely used in order to 368 
reach and maintain the antibiotic therapeutic target (10, 12, 14, 15).   369 
Our study had a prospective design and included all burn patients admitted consecutively to a 370 
tertiary hospital. Nevertheless, this study has several limitations. First, as burn patients 371 
constitute a specific and difficult population to study, the sample size is limited compared 372 
with population PK standards. However, quite rich amoxicillin concentration data were 373 
available, and PK parameters were precisely estimated. Second, as our laboratory could not 374 
dose clavulanic acid, only the amoxicillin concentration could be analysed and studied for this 375 
work. Further research is necessary to investigate the potential PK changes of clavulanic acid 376 
in burn patients and to define the PK/PD in this population. However, amoxicillin is 377 
considered as the main therapeutic agent as clavulanic acid has a very weak antibacterial 378 
activity and literature suggests that clavulanic acid has no influence on amoxicillin PK and 379 
vice-versa (59). Third, even though research is active on the field, it is still unclear which 380 
PK/PD target should be aimed for in critically ill patients (including the burn population)(11, 381 
12, 14) and experimental studies have shown that the values of fT>MIC required to produce a 382 
given effect may vary between beta-lactams (35). Fourth, this work focused only on efficacy 383 
targets and no upper threshold for toxicity endpoints was evaluated. Owing to the large 384 
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therapeutic window of amoxicillin, this should not present an important limitation to our 385 
results. Finally, simulations performed outside the data range of data should be handle 386 
cautiously. Nevertheless, this may be an adequate approach when the covariate-parameter 387 
relationships have a rational basis. Regarding body weight, the use of allometric scaling to 388 
describe the relationship between V1 and BW is a reasonable approach for simulating the 389 
effect of weight on the PK based on the theories of allometry and scaling (60). Regarding 390 
renal function, the simulation was based on the linear correlation found between amoxicillin 391 
clearance and creatinine clearance which is in accordance with renal clearance concepts. 392 
In conclusion, to the best of our knowledge, this is the first population analysis of 393 
amoxicillin PK data in burn patients showing increased typical values and important 394 
variability in amoxicillin CL compared to literature data with non-burn patients. This work 395 
highlights the need for a higher dosage and a longer infusion of amoxicillin in burn ICU 396 
patients with augmented CLR infected by microorganisms with high MIC values.   397 
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HPLC-MS/MS High-performance liquid chromatography coupled with tandem mass 404 
spectrometry 405 
ICU Intensive care unit 406 
MIC   Minimum inhibitory concentration 407 
OFV   Objective function value 408 
PK   Pharmacokinetic 409 
PD   Pharmacodynamic 410 
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Figure Legends 613 
 614 
Figure 1. Model-derived conditional weighted residuals versus population predictions (upper 615 
panel) and time (lower panel). 616 
 617 
Figure 2. Prediction-corrected visual predictive check obtained with the final model. The 618 
open circles represent the observed concentrations. The grey solid and dashed lines represent 619 
the median and the 5
th
/95
th
 percentiles of the observed concentrations, respectively. The dark 620 
and light grey areas represent the 95% CI of the simulated median and 5
th
/95
th
 percentiles, 621 
respectively. Of note, three observations greater than 100 mg/L are not shown for ease of 622 
graphical display (105.7, 134.4 and 198 mg/L). 623 
 624 
Figure 3. Observed vs. population/individual predictions (linear scale). Circles represent 625 
population predictions and black dots individual predictions. The line is y = x. 626 
 627 
Figure 4. Probability of target attainment as a function of the MIC and dosage regimen for six 628 
stages of renal function. IT indicates infusion time. The left and right panel shows the results 629 
for the low (fT>MIC ≥ 50%) and high (fT>MIC = 100%) pharmacodynamic target 630 
respectively.  631 
 632 
  633 
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Table 1. Characteristics of the burn patients who received amoxicillin 634 
 635 
    
    
Characteristic Value 
    
Number of patients 21 
Male, n (%) 16 (76.2) 
Age (years), mean (± SD) 50.1 (24.3) 
Body weight at admission (kg), median (IQR) 72.4 [67.0–83.6] 
Initial CLCR (mL/min), median (IQR)* 128 [65–150] 
TBSA affected (%), median (IQR) 23 [12.5–44] 
< 20 (n, %)  7 (33.3) 
20–40 (n, %) 9 (42.9) 
41–60 (n, %) 2 (9.5) 
> 60 (n, %) 3 (14.3) 
SAPS II, mean (± SD) 35.9 (18.6) 
Ryan score, median (IQR) 1 [1–2] 
Inhalation lesions, n (%) 16 (76.2) 
Length of ICU stay, median (IQR) 23 [13.0–39.5] 
Mortality in the burn ICU, n (%) 2 (9.5) 
 636 
* Using Cockcroft and Gault formula.  637 
 638 
IQR: Interquartile range; SAPS II: Simplified Acute Physiology Score; SD: Standard deviation;  639 
TBSA: total body surface area.  640 
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Table 2. Microbiological data 641 
 642 
 643 
 Number of 
isolates 
Median MIC 
(min–max) 
Antimicrobial therapy 
Gram-negative 
bacteria 
5 2 (1–4) mg/L Amoxicillin + clavulanic acid (n = 5) 
Gram-positive 
bacteria 
15 0.5 (0.016–2) mg/L 
Amoxicillin (n = 3) 
Amoxicillin + clavulanic acid (n = 12) 
Gram-negative species: Haemophilus influenzae (n = 2), Klebsiella pneumoniae, Citrobacter koseri, Pantoea 644 
spp. 645 
Gram-positive species: Staphylococcus aureus (n = 6), Streptococcus pneumoniae (n = 5), Streptococcus bovis, 646 
Enterococcus faecalis, Granulicatella adiacens, Bacillus spp.  647 
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Table 3. Population PK parameters of amoxicillin 648 
Parameter Structural model  
mean estimate (RSE) 
Covariate model  
mean estimate (RSE) 
Bootstrap  
mean estimate (95% CI) 
Fixed effects   
CL (L/h) 13.1 (12%) 13.6 (8%) 13.7 (11.5–16.5) 
CLCR_CL - 0.57 (25%) 0.53 (0.19–0.79) 
V1 (L) 10.1 (25%) 9.73 (20%) 9.6 (4.5–16.4) 
Q (L/h) 20.8 (31%) 20.1 (24%) 20.2 (12.6–52.5) 
V2 (L) 16.6 (15%) 17.6 (14%) 17.4 (13.0–24.2) 
Random effect    
ωCL (CV%) 57.3 (16%) 37.3 (19%) 36.0 (21.7–53.2) 
Residual variability    
Proportional error 
(%) 
34.4 (20%) 37 (19%) 34.6 (22.1–47.5) 
Additive error 
(mg/L) 
0.59 (31%) 0.08 (10%) 0.08 (0.07–0.93) 
 649 
CL: clearance, V1: central volume of distribution, RSE: relative standard error; 95% CI: 650 
95% confidence interval, CLCR_CL proportional increase in CL elimination as a function of 651 
CLcr, CL: interpatient variability on CL. 652 
 653 
The final models are as follows: 654 
TVCL = CL*(1 + CLCR_CL*(CLCR – 110)) 655 
TVV1 = V1 *(BW/70) 656 
where CLCR is estimated by the Cockcroft-Gault equation (mL/min), 110 ml/min is average 657 
CLCr in our populationand BW is body weight (kg).  658 
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Table 4. Probability of target attainment stratified by body weight and renal function 659 
for a dosage of 1 g q8 h and a MIC of 8 mg/L  660 
 661 
CLCR Body weight fT>MIC 
PTA 
fT>MIC ≥ 50% 
PTA 
fT>MIC = 100% 
30 mL/min 
50 kg 0.65 (0.24) 0.69 0.17 
70 kg 0.68 (0.24) 0.73 0.21 
100 kg 0.72 (0.24) 0.77 0.26 
150 kg 0.76 (0.23) 0.82 0.32 
100 mL/min 
50 kg 0.34 (0.18) 0.16 0.008 
70 kg 0.36 (0.19) 0.19 0.01 
100 kg 0.38 (0.20) 0.22 0.02 
150 kg 0.42 (0.21) 0.27 0.04 
200 mL/min 
50 kg 0.18 (0.10) 0.012 0 
70 kg 0.19 (0.10) 0.018 0 
100 kg 0.21 (0.11) 0.03 0 
150 kg 0.23 (0.12) 0.04 0 
 662 
CLCR: Creatinine clearance, fT>MIC: Cumulative percentage of a 24 h period that the 663 
unbound fraction of a drug exceeds the MIC at steady-state pharmacokinetic conditions, 664 
PTA: probability of target achievement.  665 
 o
n
 N
ovem
ber 5, 2018 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
  
28 
Figure 1 666 
 667 
 668 
  669 
Figure 1. Model-derived conditional weighted residuals versus population predictions (upper 670 
panel) and time (lower panel).  671 
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Figure 2 672 
 673 
 674 
 675 
Figure 2. Prediction-corrected visual predictive check obtained with the final model. The 676 
open circles represent the observed concentrations. The grey solid and dashed lines represent 677 
the median and the 5
th
/95
th
 percentiles of the observed concentrations, respectively. The dark 678 
and light grey areas represent the 95% CI of the simulated median and 5
th
/95
th
 percentiles, 679 
respectively. Of note, three observations greater than 100 mg/L are not shown for ease of 680 
graphical display (105.7, 134.4 and 198 mg/L).  681 
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Figure 3 682 
 683 
 684 
 685 
 686 
Figure 3. Observed vs. population/individual predictions (linear scale). Circles represent 687 
population predictions and black dots individual predictions. The line is y = x. 688 
 689 
 690 
 691 
 692 
 693 
 694 
 695 
 696 
 697 
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Figure 4  698 
 699 
 700 
 701 
 702 
 703 
 704 
 705 
 706 
 707 
 708 
 709 
 710 
 711 
 712 
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Figure 4 (continued) 713 
 714 
 715 
 716 
Figure 4. Probability of target attainment as a function of the MIC and dosage regimen for six 717 
stages of renal function. IT indicates infusion time. The left and right panel shows the results 718 
for the low (fT>MIC ≥ 50%) and high (fT>MIC = 100%) pharmacodynamic target 719 
respectively. 720 
 721 
 722 
 723 
 724 
 725 
 726 
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